- The Data Minute podcast: Fundraising in biotech
- The conversation with Darren Cooke
- Where to watch, share, and subscribe to The Data Minute
- Previous episodes
- Raise amount vs. valuation cap: What the data tells us (Mendel Chuang, Acquired Wisdom Fund): May 27
- The state of startup compensation today: May 13
- What did the pandemic due to healthtech investing (Marissa Bertorelli, Polaris Partners): April 29
- How many checks should founders expect in their pre-seed round? (Dave Anderson, Beat Ventures): April 15
In this week’s episode of The Data Minute, Peter Walker (Head of Insights at Carta) sits down with Darren Cooke (Executive Director, Berkeley Life Sciences Entrepreneurship Center) for an enlightening discussion about some emerging trends with biotech companies: Namely, while pharma and biotech currently rank as the 5th most-funded type of pre-seed startups, they simultaneously enjoy favorable valuations to other SaaS-type businesses.
This leads Peter and Darren into a conversation about biotech, the challenges and differences for biotech founders when raising seed capital, and of course, Darren’s history and experience leading Berkeley’s accelerator program, SkyDeck—one of the most celebrated accelerators in the startup world.
>> Subscribe to Carta’s weekly Data Minute newsletter>> Explore interactive startup and VC data
The conversation with Darren Cooke
00:00 Intro
00:44 Darren Cooke, Berkeley Life Sciences Entrepreneurship Center
02:05 Berkeley SkyDeck
04:39 The pre-seed experience for biotech companies
08:22 Regulation, reimbursement, and outside funding
10:29 Round sizes in the biotech industry
12:27 Investor interest in biotech
16:42 The five stakeholders biotech companies need to know
21:15 Pre-seed fundraising and priced rounds
23:27 Demo day
25:52 Words of advice